Tumor hypoxia is a unique feature of most solid tumors including treatment‐resistant TNBCs and remains a barrier to their successful treatment.[42, 58] Thus, in this study, we demonstrate the potential of hypoxia‐specific delivery of AZD6738 to selectively eradicate hypoxic cancer cells, whilst minimising the normal cell toxicities associated with ATR inhibition. Here, ATR is linked to cancer.